Skip to main content

Table 1 Time from initial hematologic malignancy diagnosis to HCT by type of hematologic malignancy. All commercially insured patients included. HCT, hematopoietic cell transplantation; SD, standard deviation

From: Healthcare utilization and cost of cancer-related care prior to allogeneic hematopoietic cell transplantation for hematologic malignancies in the US: a retrospective real-world analysis

Diagnosis

Months to HCT

Proportion of patients with ≤ 6, > 6 and < 12, and ≥ 12 months between their initial diagnosis and HCT

Mean (SD)

Median

≤6 months

> 6 and < 12 months

≥12 months

All patients (N = 2663)

12.5 (15.7)

6.3

1287 (48.3%)

573 (21.5%)

807 (30.2%)

Acute lymphocytic leukemia (N = 346)

8.1 (10.0)

4.9

210 (60.7%)

82 (23.7%)

54 (15.6%)

Acute myelogenous leukemia (N = 984)

8.1 (10.5)

4.4

650 (66.1%)

156 (15.9%)

178 (18.0%)

Non-Hodgkin’s lymphoma (N = 447)

21.0 (20.8)

13.7

97 (21.7%)

105 (23.5%)

245 (54.8%)

Myelodysplastic syndrome (N = 330)

12.4 (17.4)

6.4

154 (46.7%)

90 (27.3%)

86 (26.0%)

Myeloproliferative disorders (N = 148)

14.5 (18.6)

7.8

61 (41.2%)

36 (24.3%)

51 (34.5%)